Moderna (MRNA)
(Real Time Quote from BATS)
$133.89 USD
+0.99 (0.75%)
Updated May 20, 2024 09:40 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
MRNA 133.89 +0.99(0.75%)
Will MRNA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRNA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRNA
Here's Why Merck (MRK) Stock Has Outperformed Industry YTD
The Zacks Analyst Blog Highlights Novavax, Sanofi, Fulcrum Therapeutics, Moderna and Bristol Myers
MRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Merck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Stock Market News for May 14, 2024
Other News for MRNA
Wall Street Breakfast: What Moved Markets
Novo Nordisk, J&J lead R&D rankings in big pharma: report
10 Health Care Stocks Whale Activity In Today's Session
Moderna vaccine patent upheld by European Patent Office: report
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech